ストックスクリーナーアプリを入手
1.14
6.56%
-0.08
アフターアワーズ：
1.13
-0.01
-0.88%
Hcw Biologics Inc (HCWB) 最新ニュース
HCW Biologics Inc. Files Form 8-K with SEC Detailing Company and Stock Information - Minichart
HCW Biologics (HCWB) AGM 2026 Summary - Quartr
Shareholders back HCW Biologics (NASDAQ: HCWB) 2026 board slate - Stock Titan
HCW Biologics takes back rights to commercial-ready reagents - MSN
HCW Biologics Inc Stock Short Interest Rises to 58.43% - Quiver Quantitative
HCWB Announces Selling Shareholder Plans for 5.69M Shares - GuruFocus
HCW Biologics Registers Resale of Up to 5.7 Million Shares - marketscreener.com
HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock - TradingView
HCW Biologics (HCWB) files S-1 for resale of 5.69M PIPE shares and warrants - Stock Titan
HCW Biologics Inc. (HCWB) Holds Steady as Shares Consolidate Between Key Support and ResistanceWeak Sell Signals - newsline.com
Nasdaq Deadline Looms for HCW Biologics as Stock Slips Toward $1 Mark - Bez Kabli
Clark Hill Advises HCW Biologics in $4.0 Million PIPE Offering | News & Events | Clark Hill PLC - Clark Hill
HCW Biologics Wins Nasdaq Extension to Avoid Delisting - The Globe and Mail
HCWB Stock Price, Quote & Chart | HCW BIOLOGICS INC (NASDAQ:HCWB) - ChartMill
HCW Biologics Inc. Files Form 8-K with SEC: Company Details, Stock Information, and Emerging Growth Status - Minichart
Nasdaq grants HCW Biologics extension to regain minimum bid compliance By Investing.com - Investing.com Canada
Nasdaq grants HCW Biologics extension to regain minimum bid compliance - Investing.com UK
HCW Biologics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
HCW Biologics (HCWB) granted Nasdaq extension to fix $1 bid price deficiency - Stock Titan
MSN Money - MSN
HCW Biologics, Inc. Financial Disclosures & SEC Filings - TradingView
Maxim Group Maintains HCW Biologics(HCWB.US) With Buy Rating, Raises Target Price to $5 - Moomoo
Maxim Group Maintains HCW Biologics(HCWB.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
HCWB Maintained by Maxim Group -- Price Target Raised to $5.00 - GuruFocus
Top insider buys and sells disclosed for Wednesday By Investing.com - Investing.com UK
HCW Biologics CFO Rebecca Byam buys $20,000 in common stock By Investing.com - Investing.com Canada
HCW Biologics CEO Wong buys $159,999 in common stock By Investing.com - Investing.com South Africa
HCW Biologics CEO Wong buys $159,999 in common stock - Investing.com
HCW Biologics CFO Rebecca Byam buys $20,000 in common stock - Investing.com
HCW Biologics director Scott T. Garrett purchases $250,000 in stock - Investing.com
HCW Biologics director Scott T. Garrett purchases $250,000 in stock By Investing.com - Investing.com Canada
HCW Biologics (HCWB) CEO boosts stake with stock and warrant buys - Stock Titan
HCW Biologics (HCWB) director adds common shares and long-dated warrants - Stock Titan
HCW Biologics CFO buys shares and warrants | HCWB Insider Trading - Stock Titan
HCWB Regains Ex Vivo Rights for Key Compounds - GuruFocus
HCW Biologics regains ex vivo rights to CAR-T therapy reagents - Investing.com UK
HCW Biologics regains ex vivo rights to CAR-T therapy reagents By Investing.com - Investing.com South Africa
HCW Biologics (NASDAQ: HCWB) ends Wugen license, keeps 2.2M shares - Stock Titan
HCW Biologics to regain full rights for two commercial-ready reagents from Wugen - marketscreener.com
HCW Biologics To Regain Full Rights For Two Commercial-Ready Reagents From Wugen - TradingView
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen - GlobeNewswire
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):